Axsome Therapeutics (AXSM) Cash from Financing Activities (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Cash from Financing Activities data on file, last reported at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 89.77% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $75.2 million (down 14.85% YoY), and the FY2025 full-year result was $101.5 million, up 75.42% from the prior year.
• Cash from Financing Activities slipped to $3.0 million in Q1 2026, from $16.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $246.1 million in Q2 2023 to a low of -$1.2 million in Q1 2024.
• A 5-year average of $45.8 million and a median of $29.3 million in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 712300.0% in 2024, while the deepest fall reached 102.3% in 2024.
• Tracing AXSM's Cash from Financing Activities over 5 years: stood at $1.1 million in 2022, then sank by 100.19% to -$2000.0 in 2023, then jumped by 712300.0% to $14.2 million in 2024, then gained by 15.03% to $16.4 million in 2025, then tumbled by 81.73% to $3.0 million in 2026.
• Business Quant data shows AXSM's Cash from Financing Activities at $3.0 million in Q1 2026, $16.4 million in Q4 2025, and $21.3 million in Q3 2025.